ClinicalTrials.gg
RecruitingNCT07181018TWINSPLUpdated Sep 18, 2025

Metabolic Syndrome Among Polish Twins

An observational study in Twins and Metabolic Syndrome, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to participants aged 15 Years to 44 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Poznan University of Medical Sciences · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
15 Years to 44 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Metabolic Syndrome with a site in Poland — 10 open to participants now, 13 under way, 1 of them phase 3. Metabolic Syndrome · Poland.

Planned enrollment
2nd of 12
1,500 · median 143
Started
2025
with 3 others
Observational
12 of 31
8 open now
Primary completion
2028-09
later than 12 of 12 live
Registered
25th of 31
by date
Lead sponsor
4 of 31
Poznan University of Medical Sciences

Among the 31 studies in Metabolic Syndrome with a site in Poland, this one is the 2nd largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 25th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

10 of the 31 studies in Metabolic Syndrome with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 15 Years to 44 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Metabolic Syndrome with a site in Poland, or all of them as a file.
02

Study summary

Over a 5-year follow-up period, we aim to conduct a study among twins aged 15-44 years from the Polish population with the following objectives:

  1. To determine the incidence and risk factors for the development of de novo metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, or cirrhosis. We also intend to evaluate the progression of hepatic steatosis from early to advanced stages or toward fibrosis/cirrhosis.
  2. To determine the prevalence and identify predictive factors for the onset and progression of features, diseases, or complications of metabolic syndrome (MS) other than liver disease, particularly within the spectrum of metabolic, nutritional, cardiovascular, endocrine, oncological, psychological, and other disorders typically associated with MS.
  3. To assess the association between previous COVID-19 infection or long-COVID features and the occurrence of MASLD, liver fibrosis, or cirrhosis due to MASLD, as well as other features, diseases, or complications of MS.
  4. To evaluate the prevalence of malignancies in a young twin population (aged 15-44 years) with MS or with risk factors for MS.
  5. To investigate the contribution of genetic and environmental factors and gut microbiota composition to the development and progression of structural liver changes (steatosis, fibrosis, cirrhosis) in MASLD, as well as other features and complications of MS in twins discordant for the MS phenotype.
  6. To assess the role of genetic and environmental components in the occurrence and severity of MS phenotype discordance in monozygotic twins.
03

Conditions studied

  • Twins
  • Metabolic Syndrome

Browse trials for

04

Who can participate

Ages eligible
15 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population comprises Polish twin individuals aged 15-44 years, who have provided informed consent, have a living co-twin, and present a positive family history (first- or second-degree relatives) of metabolic syndrome, its related comorbidities, or common complications.

Eligibility criteria

Inclusion Criteria

1. Age between 15 and 44 years. 2. Provision of to participate in the study. 3. Twin with a living co-twin. 4. Positive family history in first- and second-degree relatives of metabolic syndrome (MS), associated diseases, or the most common complications of the syndrome.

________________________________________ Exclusion Criteria

Permanent exclusion criteria:

  1. Co-twin does not consent to participate in the study.
  2. Inability to obtain medical history of biological family members.
  3. Presence of advanced liver fibrosis, cirrhosis, or liver cancer.
  4. Known liver genetic disorders, hepatitis, celiac disease, hemochromatosis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), cystic fibrosis, or Wilson's disease.
  5. Current or chronic alcohol consumption >20 g of ethanol/day in women and >30 g/day in men.
  6. Short bowel syndrome.
  7. Cyanotic congenital heart defect.
  8. Myasthenia.
  9. Central nervous system degenerative diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease.
  10. Storage diseases involving the liver.
  11. Active malignant neoplasm undergoing treatment (excluding non-melanoma skin cancers and melanoma treated non-pharmacologically).
  12. Chronic kidney disease requiring renal replacement therapy.
  13. Status post organ or tissue transplantation requiring .
  14. Pituitary, hypothalamic, or adrenal hyperfunction/hypofunction requiring hormone supplementation.
  15. Addiction to psychoactive substances or drugs.
  16. Other severe and incurable diseases that, in the investigator's opinion, constitute a permanent for participation in the study.
  17. Lack of cooperation by the volunteer during the visit to the Research Center. ________________________________________

Temporary exclusion criteria (after resolution, the volunteer may be enrolled):

  1. Acute infection, low-grade fever or fever, or use of antibiotics at the time of recruitment or prior to the visit at the Research Center - inclusion possible after 6 weeks.
  2. Any vaccination within the past 6 weeks.
  3. Pregnancy and up to 6 months postpartum.
  4. 3 months after the natural cessation of breastfeeding.
  5. 3 months after surgery (does not apply to minor surgical procedures).
  6. Untreated hyperthyroidism or hypothyroidism - inclusion possible 3 months after achieving euthyroidism.
  7. Significant weight loss or gain in the past 3 months (>10% of initial body weight) - inclusion possible 3 months after weight stabilization.
  8. 6 months after discontinuation of temporary parenteral or enteral nutrition via feeding tube.
  9. 12 months after bariatric surgery.
  10. Systemic treatment with , chemotherapy, immunosuppressive drugs, or biological therapy known to be hepatotoxic or potentially inducing abnormalities found in MS - inclusion possible at least 3 months after completing therapy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • OtherTrial within cohort (TWIC)

    Educational intervention based on a protocol specifically developed for the TWINS.PL cohort, aimed at activating and engaging the participant in the intervention process. Intervention group: Phenotypically concordant participants from the TWINS.PL STUDY cohort, randomized to receive an educational intervention designed to actively engage them in modifying selected health-relevant endpoints. Control group: The co-twin of the participant randomized to the intervention arm, serving as the control. 1. TWINS-TWIC HL: Research Question: Does participation in a structured, participant-activating educational intervention program influence health literacy indicators among participants of the TWINS.PL study? Study Design: A randomized controlled trial embedded within a prospective observational twin cohort (TWiC study in a twin cohort). 2. TWINS-TWIC DIET Research Question: Does participation in a structured, participant-activating educational intervention focused on dietary habits influence the

06

What researchers measure

Primary outcomes

  1. De novo occurrence of metabolic steatosis, hepatic fibrosis, or cirrhosis.

    De novo occurrence of metabolic steatosis, hepatic fibrosis, or cirrhosis based on assessment by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and/or transient elastography.

    Time frame: Baseline up to approximately 5 years

  2. Progression of hepatic steatosis or fibrosis to more advanced stages or cirrhosis.

    Progression of hepatic steatosis or fibrosis to more advanced stages or cirrhosis, as assessed by magnetic resonance imaging and dynamic elastography, using the following evaluation scales: * The hepatic steatosis grading scale based on magnetic resonance imaging-proton density fat fraction (MRI-PDFF); * The hepatic steatosis grading scale based on dynamic elastography using the Controlled Attenuation Parameter (CAP) technique; * The liver fibrosis grading scale assessed by dynamic elastography using liver stiffness (LS) measurement, according to the METAVIR scoring system

    Time frame: Baseline up to approximately 5 years

Secondary outcomes

  1. First-time occurrence of overweight or obesity

    Overweight will be defined as a BMI of 25 to \<30 kg/m², and obesity as a BMI of ≥30 kg/m²

    Time frame: Baseline to approximately 5 years

  2. First-time occurrence of an increase in visceral adipose tissue

    Increase in visceral adipose tissue \>10%, as assessed by DEXA or BIA

    Time frame: Baseline to approximately 5 years

  3. First-time occurrence of Prediabetes or type 2 diabetes mellitus (T2DM)

    First diagnosis of prediabetes or type 2 diabetes mellitus (T2DM), confirmed by standard laboratory criteria (fasting plasma glucose, HbA1c, or oral glucose tolerance test) in accordance with current ADA/EASD guidelines

    Time frame: Baseline to approximately 5 years

  4. The assessment of HOMA-IR

    First-time occurrence of HOMA-IR \>5

    Time frame: Baseline to approximately 5 years

  5. First-time occurrence of Pancreatic steatosis

    Visualization of pancreatic steatosis during abdominal ultrasound and/or MRI-PDFF

    Time frame: Baseline to approximately 5 years

  6. First-time occurrence of Hypertension (HTN)

    Diagnosis of arterial hypertension according to the ESC/ESH definition

    Time frame: Baseline to approximately 5 years

  7. First-time occurrence of Acute coronary syndrome, the need for coronary artery bypass grafting (CABG), any percutaneous coronary intervention (PCI), or detection of regional wall motion abnormalities on echocardiography

    All outcome events will be confirmed through review of medical records, including hospitalization reports, procedural documentation, and echocardiographic findings, in accordance with the most recent ESC guidelines on Acute Coronary Syndromes.

    Time frame: Baseline to approximately 5 years

  8. First-time occurrence of Systolic heart failure with a reduced left ventricular ejection fraction of less than 45%

    Diagnosis of systolic heart failure confirmed by echocardiographic assessment showing a left ventricular ejection fraction (LVEF) \<45%.

    Time frame: Baseline to approximately 5 years

  9. First-time occurrence of Atrial fibrillation/flutter

    First documented episode of atrial fibrillation (paroxysmal, persistent, or permanent) or atrial flutter, confirmed by ECG or other cardiac monitoring, or the need for pulmonary vein isolation and/or cavotricuspid isthmus ablation.

    Time frame: Baseline to approximately 5 years

  10. First-time occurrence of Requirement for angioplasty, stenting, or surgery of the aorta or any other arteries (excluding trauma-related causes)

    First requirement for angioplasty, stent placement, or surgical intervention of the aorta or other arteries (excluding trauma-related procedures), confirmed by medical records and procedural documentation.

    Time frame: Baseline to approximately 5 years

  11. First-time occurrence of Implantation of a cardiac electronic device

    First implantation of a cardiac electronic device (e.g., pacemaker, ICD, or CRT) indicated for sick sinus syndrome, advanced atrioventricular conduction abnormalities, or ischemic heart disease, as confirmed by procedural documentation.

    Time frame: Baseline to approximately 5 years

  12. First-time occurrence of Transient ischemic attack (TIA) or ischemic stroke

    First documented occurrence of transient ischemic attack (TIA) or ischemic stroke, confirmed by neurological assessment and/or neuroimaging, in accordance with current ESC guidelines.

    Time frame: Baseline to approximately 5 years

  13. First-time occurrence of Hashimoto's thyroiditis

    Increase of at least one anti-thyroid autoantibody - anti-thyroid peroxidase and/or anti-thyroglobulin, accompanied by typical ultrasound picture suggesting Hashimoto's thyroiditis, namely irregular, decreased echogenicity of thyroid parenchyma, signs of fibrosis and decreased vascularity on Color Doppler examination

    Time frame: Baseline to approximately 5 years

  14. First-time occurrence of Focal thyroid lesions detected on ultrasound

    Focal thyroid lesions detected on ultrasound (≥1 lesion with a diameter \>5 mm)

    Time frame: Baseline to approximately 5 years

  15. First-time occurrence of Adrenal incidentaloma

    Adrenal lesion \>10 mm in diameter

    Time frame: Baseline to approximately 5 years

  16. First-time occurrence of Malignancy with a known potential association with insulin resistance

    e.g., colorectal, thyroid, breast, endometrial, hepatic, pancreatic, renal, gallbladder, esophageal, or ovarian cancer

    Time frame: Baseline to approximately 5 years

  17. First-time occurrence of Long COVID-19 syndrome

    Defined as persistent (over 12 weeks) symptoms (listed in the questionnaire filled out by the patient), which appeared after COVID-19 infection and their occurrence cannot be explained by other causes

    Time frame: Baseline to approximately 5 years

  18. Death from non-accidental causes

    The number of deaths from non accidental causes during the observation period

    Time frame: Baseline to approximately 5 years

  19. The assessment of HbA1c

    First-time occurrence of HbA1c \>5.7%

    Time frame: Baseline to approximately 5 years

07

Study locations

1 of 1 sites recruiting
  • Uniwersytecki Szpital Kliniczny
    Poznan, Wielkopolska 60-355, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 150 non-industry observational studies under Metabolic Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 106. This study's planned 36 months is below that.

Counting every sponsor, half of 161 studies reached it within 42 months; a quarter within 18 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2033
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07181018
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Sep 1, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2033 (estimated)
Last update
Sep 18, 2025

Study contacts

Piotr Eder, MD, Profesor
Contact
piotreder@ump.edu.pl
+(48) 618691343

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion